Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: Provided are various embodiments relating to long-acting anti-IL31 antibodies binding to canine IL31 and/or feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: According to an aspect of the disclosure, a method for displaying content on a display of an electronic device comprises determining, based on information about the content, a first region of the display on which a first portion of the content is to be displayed; obtaining an angle between the first region and a second region of the display, the second region being distinguished from the first region; generating, based on the angle and a location of a user, correction content corresponding to a second portion of the content; and displaying the first portion on the first region, and displaying the correction content on the second region.

Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: According to an aspect of the disclosure, a method for displaying content on a display of an electronic device comprises determining, based on information about the content, a first region of the display on which a first portion of the content is to be displayed; obtaining an angle between the first region and a second region of the display, the second region being distinguished from the first region; generating, based on the angle and a location of a user, correction content corresponding to a second portion of the content; and displaying the first portion on the first region, and displaying the correction content on the second region.

Abstract: Aspects of the invention include an optimal interpretable decision tree using integer linear programming techniques. A non-limiting example computer-implemented method includes receiving, using a processor, a plurality of data inputs from a process and selecting, using the processor, a data subset from the plurality of data inputs by solving linear programming to obtain a solution. The method builds and optimizes, using the processor, an optimal decision tree based on the data subset and alerts, using the processor, a user when a prediction of the optimal decision tree is greater than a threshold value.

Abstract: Provided are various embodiments relating to anti-IL31 antibodies binding to canine IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines, felines, and equines.

Abstract: Provided are various embodiments relating to feline erythropoietin (EPO) polypeptide analogs with one or more additional glycosylation sites and methods of producing and using the same to treat anemia in companion animals. Also provided are various embodiments relating to EPO polypeptides having a mutation in the second binding site, polypeptides comprising an extracellular domain of EPO receptor, and methods of using the same for treating polycythemia in mammals.

Abstract: Aspects of the invention include implemented method includes selecting an optimization algorithm for the control system of a processing plant based on whether the control system is guided by a linear-based predictive model or a non-linear-based predictive model, in which a gradient is available. Calculating set-point variables using the optimization algorithm. Predicting an output based on the calculated set-point variables. Comparing an actual output at the processing plant to the predicted output. Suspending a physical process at the processing plant in response to the actual output being a threshold value apart from the predicted output.

Abstract: A contact device includes an outer housing delimiting an inner space and an inner housing arranged in the inner space, the inner housing having a first recess. The contact device includes a contact element arranged in the inner space and a sealing element arranged between the contact element and the outer housing. The sealing element seals the inner space from the environment. The contact element has a second recess on an outside of the contact element aligned with the first recess. The contact device includes a contact securing device movable along the first recess to engage the second recess of the contact element.

Abstract: The present invention provides a method for speech separation and recognition. The present invention overcomes the disadvantages of the existing techniques by providing automatic speech recognition and separation that helps managers see what their service agents and customers are saying. From there, quickly and objectively knowing the wishes and concerns of customers as well as whether their service agents can give accurate and correct advice. In addition, the system is constantly updated based on the semi-supervised training mechanism, which means that the system can self-learn from actual data during operation, thereby helping to improve the system's accuracy.

Abstract: According to an aspect of the disclosure, a method for displaying content on a display of an electronic device comprises determining, based on information about the content, a first region of the display on which a first portion of the content is to be displayed; obtaining an angle between the first region and a second region of the display, the second region being distinguished from the first region; generating, based on the angle and a location of a user, correction content corresponding to a second portion of the content; and displaying the first portion on the first region, and displaying the correction content on the second region.

Abstract: Provided are various embodiments relating to anti-IL31 antibodies having enhanced binding to canine IL31 and feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines and felines. Antibodies with enhanced binding to canine IL31 and feline IL31 are provided Antibody heavy chains and light chains that are capable of forming antibodies that bind canine and feline IL31 are also provided.

Abstract: Provided are various embodiments relating to parvovirus antibodies, including caninized, felinized, and chimeric antibodies, that bind to canine and/or feline parvovirus, for example, having improved expression characteristics. In various embodiments, the parvovirus antibodies have ADCC, ADCP, and/or CDC effector functions. In various embodiments, such monoclonal parvovirus antibodies can be used in methods to prevent and/or treat parvoviral infection in subjects, such as dogs and cats. For example, the parvovirus antibodies provided may be used to provide passive immunity against infection with a canine or feline parvovirus.

Abstract: A cloud computing capacity management system can include a fine-grained admission control layer, a policy engine, and an enforcement layer. The fine-grained admission control layer can be configured to ingest capacity signals and create a capacity mitigation policy, based at least in part on the capacity signals, to protect available capacity of a cloud computing system for prioritized users. The capacity mitigation policy can be directed to users of the cloud computing system. The policy engine can be configured to control how the capacity mitigation policy is applied to the cloud computing system. The enforcement layer can be configured to handle incoming resource requests and to enforce resource limits based on the capacity mitigation policy as applied by the policy engine.

Abstract: A plug connector system is described. The plug connector system includes: a plug connector; a housing on which the plug connector is installed; the housing having an opening having a first inner wall; the plug connector having a sheet-metal shield that projects at least in portions into the opening; a ring being disposed in the opening and, with an outer wall, electrically contacting the first inner wall of the opening; the sheet-metal shield electrically contacting, with a further outer wall of the sheet-metal shield, a second inner wall of the ring.

Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.

Abstract: Provided are various embodiments relating to TrkA ECD polypeptides from companion animal species that bind to NGF. Such polypeptides can be used in methods to treat NGF-induced condition related to chronic pain and/or inflammatory pain in companion animals, such as canines, felines, and equines.

Abstract: Provided are various embodiments relating to anti-IL17A antibodies and IL17Ra ECD polypeptides that bind to IL17A. In various embodiments, such anti-IL17A antibodies or IL17Ra ECD polypeptides can be used in methods to treat IL17-induced conditions in subjects, such as humans or companion animals, such as canines, felines, and equines. Also provided are various embodiments relating to IgG Fc variant polypeptides having one or more amino acid substitutions for reducing binding to C1q and/or CD16. In some embodiments, the IgG Fc variants and/or polypeptides comprising the IgG Fc variants (e.g., fusion polypeptides comprising the IgG Fc variants and the anti-IL17A antibodies and/or IL17Ra ECD polypeptides described herein) may have reduced complement-mediated immune responses and/or antibody-dependent cell-mediated cytotoxicity.

Abstract: Provided are various embodiments relating to variant IgG Fc polypeptides of companion animals having increased Protein A binding for ease of purification, decreased C1q binding for reduced complement-mediated immune responses, decreased CD 16 binding (e.g., for reduced antibody-dependent cellular cytotoxicity (ADCC) induction), increased stability, and/or the ability to form multimeric proteins. In addition, various embodiments relating to antibodies and fusion proteins comprising such variant IgG Fc polypeptides are provided. In various embodiments, such polypeptides may be used to treat companion animals, such as canines, felines, and equines.